Approval was based on results from the Phase IIIb FLOW trial, which demonstrated a 24% relative risk reduction in kidney ...

The FDA has approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening and cardiovascular death in those with T2D and CKD.

The Food and Drug Administration approved Novo Nordisk’s Ozempic as the first GLP-1 treatment option for people with type 2 ...

The FDA's move may change how doctors treat chronic kidney disease, which, according to Ozempic maker Novo Nordisk, affects around 37 million Americans and is one of the leading causes of death in the ...

The FDA’s approval of Ozempic to battle chronic kidney disease “allows us to more broadly address conditions within cardiovascular-kidney-metabolic syndrome, which affects millions of ...

Semaglutide is now approved for reducing the risk for worsening kidney disease and cardiovascular death in adults with ...

has officially approved Ozempic to help reduce the risk of serious kidney complications in people with type 2 diabetes and ...

Learn how chronic kidney disease and diabetes accelerate heart risk, with new research revealing early warning signs.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

The US Food and Drug Administration on Tuesday approved Ozempic for adults with type 2 diabetes and chronic kidney disease (CKD). The drug is now indicated specifically to treat kidney failure, ...

Body-weight cycling (also known as yo-yo dieting) has been shown to significantly increase the risk of kidney disease in people ... and in people with type 2 diabetes, and more recently in type ...

Chronic kidney disease has been linked to yo-yo dieting (also known as body-weight cycling) in the general population, which ...